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ABSTRACT
Objectives: This is the second of the two papers
introducing a cardiovascular disease (CVD) policy
model. The first paper described the structure and
statistical underpinning of the state-transition model,
demonstrating how life expectancy estimates are
generated for individuals defined by ASSIGN risk
factors. This second paper describes how the model is
prepared to undertake economic evaluation.
Design: To generate quality-adjusted life expectancy
(QALE), the Scottish Health Survey was used to
estimate background morbidity (health utilities) and the
impact of CVD events (utility decrements). The SF-6D
algorithm generated utilities and decrements were
modelled using ordinary least squares (OLS).
To generate lifetime hospital costs, the Scottish Heart
Health Extended Cohort (SHHEC) was linked to the
Scottish morbidity and death records (SMR) to cost
each continuous inpatient stay (CIS). OLS and
restricted cubic splines estimated annual costs before
and after each of the first four events. A Kaplan-Meier
sample average (KMSA) estimator was then used to
weight expected health-related quality of life and costs
by the probability of survival.
Results: The policy model predicts the change in
QALE and lifetime hospital costs as a result of an
intervention(s) modifying risk factors. Cost-
effectiveness analysis and a full uncertainty analysis
can be undertaken, including probabilistic sensitivity
analysis. Notably, the impacts according to
socioeconomic deprivation status can be made.
Conclusions: The policy model can conduct cost-
effectiveness analysis and decision analysis to inform
approaches to primary prevention, including
individually targeted and population interventions, and
to assess impacts on health inequalities.
INTRODUCTION
This paper is part 2 of a twinned set of
papers introducing an alternative cardiovas-
cular disease (CVD) policy model. The ﬁrst
paper described the structure of the state-
transition model and its statistical
underpinning, where individuals enter free
of CVD and using the ASSIGN risk factor
variables, which includes a measure of
KEY QUESTIONS
What is already known about this subject?
▸ Cardiovascular disease (CVD; rheumatic heart
diseases, hypertensive diseases, ischaemic heart
diseases, pulmonary heart disease, other forms
of heart disease, cerebrovascular diseases, dis-
eases of arteries and diseases of veins) is a
leading cause of premature mortality, morbidity
and health service costs. The incidence of CVD
has also been shown to be socially patterned.
The primary prevention of CVD is a policy prior-
ity, including the objective to reduce health
inequalities. A policy model is a model capable
of evaluating effectiveness and cost-
effectiveness of a wide range of interventions
aimed at modifying known CVD risk factors.
What does this study add?
▸ This policy model joins together risk estimation,
individual patient decision-making and societal
policymaking in a cohesive whole. By taking a
competing risk approach, the model estimates the
impact of risk factor modification on CVD events
and non-CVD mortality to predict
(quality-adjusted) life expectancy, and lifetime
health service costs. By including a measure of
socioeconomic deprivation as an independent risk
factor, the policy model can be used to assess the
impact of interventions on health inequalities.
How might this impact on clinical practice?
▸ This policy model uses the ASSIGN risk factors
to estimate CVD risk and can project the impact
of risk factor modification on (quality-adjusted)
life expectancy and lifetime health service costs.
Consequently, the model can be used consist-
ently as a clinical and policy tool, to help priori-
tise individuals for intervention and to evaluate
the effectiveness and cost-effectiveness of
interventions.
Lawson KD, Lewsey JD, Ford I, et al. Open Heart 2016;3:e000140. doi:10.1136/openhrt-2014-000140 1
Health care delivery, economics and global health care
socioeconomic deprivation, the model estimates life
expectancy.1 This second paper builds on that approach
to detail how the model is prepared to undertake eco-
nomic evaluation to assess the cost-effectiveness of inter-
ventions and the impact on health inequalities.
‘All models are wrong, but some are useful’ (George
Box). In developing a model, it is important that the
outputs generated are consistent with the needs of
decision-makers, and that the methodological approach
follows best practice guidance. Reimbursement agencies,
such as the National Institute for Health and Care
Excellence (NICE) and the Scottish Medicines
Consortium (SMC), provide guidance on undertaking
cost-effectiveness analysis of new interventions. Key
recommendations include that quality-adjusted life years
(QALYs) can be generated to account for potential mor-
bidity impacts, the impact on health service costs is esti-
mated net of intervention costs, and that a full
uncertainty analysis is undertaken.2
The International Society for Pharmacoeconomics
and Outcomes Research (ISPOR) recently produced
guidance for developing, validating and disseminating
models to undertake cost-effectiveness analysis for use in
decision analysis.3 This is intended to be generalisable
for the evaluation of health technology and public
health interventions.
There are existing policy models capable of undertak-
ing cost-effectiveness analysis, and several have been
used in practice.4 5 Models have been built using speciﬁc
national population data and are not necessarily general-
isable internationally. A systematic review of policy
models found that most focus on coronary heart disease
(CHD) only, are built using cross-sectional data, can lack
transparency in the modelling process, conduct limited
uncertainty analysis and there is a lack of validation tests
regarding outputs produced.4
Key reasons for developing this policy model include
building a model following recent guidelines and to use
the risk factors in the ASSIGN CVD risk equation,
thereby aligning the clinical tool currently used in
Scotland to screen and prioritise individuals for inter-
vention6 7 with a new policy model that can be used to
evaluate the cost-effectiveness of interventions to modify
risk. Further, by using ASSIGN, which includes a
measure of socioeconomic deprivation, a potential
novelty would be to evaluate impacts of interventions on
reducing health inequalities, which is the principal
rationale of primary prevention in Scotland.6
Consequently, the overarching intention of building this
policy model was to attempt to integrate CVD risk esti-
mation, individual patient decision-making and societal
policymaking into a cohesive whole.
The speciﬁc objectives of this second paper are to
build on the ﬁrst paper by detailing how life expectancy
estimates are quality adjusted (morbidity adjusted) to
generate quality-adjusted life expectancy (QALE) and
how individuals accumulate health service costs over esti-
mated lifetimes. The term QALE is used hereon, rather
than QALY, for exposition purposes to be consistent with
the ﬁrst paper. The paper then illustrates how the
model can estimate the cost-effectiveness of individual
and population interventions aimed at modifying risk
factors by assessing the change in QALE and lifetime
health service costs, and estimate the impact on health
inequalities.
METHODS
A description of methods is given below with technical
details available in the online supplementary appendix.
Figure 1 illustrates the structure of the state-transition
policy model which cycles annually. The ﬁrst paper
described the model in detail and demonstrated how
CVD-free individuals, deﬁned by the ASSIGN risk factor
variables, enter and transit within the model resulting in
estimates of life expectancy speciﬁc to individual risk
proﬁles. Separate model equations were estimated for
men and women while retaining the same model struc-
ture. This paper builds on these survival equations to
quality-adjust life expectancy and attach costs to indivi-
duals across expected lifetimes.
The process of quality adjusting life expectancy
While an individual may be alive, they are unlikely to be
in perfect health. There are three elements of quality
adjustment: background morbidity, the impact of experi-
encing a ﬁrst non-fatal CVD event and the impact of
experiencing subsequent non-fatal CVD events prior to
death.
Background morbidity—health-related quality of life
(HRQoL) scores (see online supplementary equation 3):
The Scottish Health Survey (SHeS) 2003,8 a representa-
tive cross-sectional survey of the general population,
included the SF-12 as a measure of HRQoL.9 A total of
7054 respondents aged 20 years plus fully completed the
SF-12, a response rate of 91% with a slight under-
representation of the most socioeconomically deprived
ﬁfth in the population (deﬁned below). No bias was
expected in the modelled results. Applying the SF-6D
algorithm to individuals’ SF-12 responses generated a
single score representing overall (preference-weighted)
HRQoL.10 Scores can range from 0.29 (worst health) to
1 (perfect health) on a linear scale. These HRQoL
scores represent background morbidity in the general
population, also known as ‘population norms’ or ‘health
utilities’. Speciﬁc estimates were modelled by sex, seven
age group categories and ﬁfths of socioeconomic depriv-
ation. Regarding age, seven categories were chosen to
be consistent with previous estimates made for the UK:11
20–25, 25–34, 35–44, 45–54, 55–64, 65–74 and 75 plus.
Regarding socioeconomic deprivation, the Scottish
Index of Multiple Deprivation (SIMD) was used, a
measure developed by the Scottish Government. SIMD
is an aggregated measure of material deprivation for
each household in Scotland and is derived from 37 indi-
cators in seven domains (income, employment, health,
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education, access to services, housing and crime) and is
determined at datazone level (geographical areas with a
population of 769).12 Each household is given a score
and the general population is divided into ﬁfths (quin-
tiles) consisting of an equal number of households.
Estimates are provided within the online supplementary
appendix.
As individuals enter the policy model, a HRQoL score
is automatically selected according to age, sex and
SIMD. The model cycles annually and the score updates
when an individual enters a new age category. The score
is used as a weighting factor to ‘quality-adjust’ an indivi-
dual’s survival probability. This process occurs within the
CVD event-free state, the two non-fatal CVD event states
and as an individual transits towards a death state.
Impact of experiencing a ﬁrst non-fatal CVD event—reducing
HRQoL scores (see online supplementary equation 4):
The SHeS 2003 was also used to estimate the impact of
experiencing (self-reported) non-fatal CVD events on
reducing HRQoL scores. These estimates are known as
‘utility decrements’. The SHeS included four CVD
events: myocardial infarction, stroke, irregular heartbeat
and intermittent claudication. Using ordinary least
squares, the impact of all four events was estimated (see
online supplementary appendix). The SHeS did not
include heart failure; however, this was considered an
important event, and the associated utility decrement
estimated by Clarke13 was used as the only available esti-
mate that we were aware of. If the ﬁrst event experi-
enced was non-fatal CHD or non-fatal cerebrovascular
disease (CBVD), the model selects the utility decrements
of myocardial infarction and stroke, respectively, to
further quality-adjust survival.
Impact of experiencing subsequent non-fatal CVD events—
further reducing HRQoL scores (see online supplementary
equations 4 and 5): From a ﬁrst non-fatal CVD event, an
individual is at risk of subsequent non-fatal CVD events
prior to death. The Scottish Heart Health Extended
Cohort (SHHEC) was linked to Scottish morbidity and
death records (SMR) to generate a dataset of over
16 000 individuals followed for an average of 21 years
(detailed in the ﬁrst paper). Probit regression was used
to estimate the annual probability of incurring any of
ﬁve non-fatal CVD events independently, following a ﬁrst
Figure 1 Structure of CVD
policy model—quality adjusting
life expectancy and estimating
lifetime health service costs.
CBVD, cerebrovascular disease;
CHD, coronary heart disease;
CVD, cardiovascular disease;
SIMD, Scottish Index of Multiple
Deprivation.
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non-fatal CHD or CBVD event, and by using restricted
cubic spline functions, event risks were extrapolated
beyond the observed follow-up period. Modelled events
include CHD, stroke, irregular heartbeat, intermittent
claudication and heart failure (see online supplemen-
tary appendix).
The probability of a speciﬁc event occurring is multi-
plied by its associated utility decrement, and summed to
generate an overall ‘composite utility decrement’. This is
used to further quality-adjust an individual’s survival.
This process is a modiﬁed version of the Kaplan-Meier
Sample Average (KMSA) estimator approach14 15 given
event risks are modelled. For exposition purposes, we
use the term KMSA estimator hereon. Finally, to gener-
ate QALE, the area under the quality-adjusted survival
curve is calculated using the trapezoid method with half-
cycle correction.
This quality adjustment process is illustrated for an
individual risk proﬁle, deﬁned as follows: a man aged
60 years, post-CHD event, no family history of CVD, non-
diabetic, SIMD score of 60.8 (highest ﬁfth of socio-
economic deprivation), systolic blood pressure of
160 mm Hg, total cholesterol of 7 mmol/L, high-density
lipoprotein (HDL) cholesterol of 1 mmol/L and smokes
20 cigarettes per day (ﬁgure 2).
Generating QALE
On entering the model, an individual is at risk of the
ﬁrst four events (non-fatal CHD, non-fatal CBVD, fatal
CVD and fatal non-CVD), one of which must occur
within 100 annual cycles. Crucially, the type and timing
of the ﬁrst event deﬁne a different scenario resulting in
speciﬁc estimates of survival, life expectancy and so
QALE. In effect, there are 400 possible scenarios (4 ﬁrst
events×100 model cycles). To generate overall, expected,
QALE, the probability of each scenario occurring (taken
from the cumulative incidence of the ﬁrst four events;
see the ﬁrst paper) is multiplied by its associated QALE
estimate, and summed.
The policy model discriminates between individual
risk proﬁles to produce speciﬁc estimates of event risks,
survival, life expectancy and QALE. For illustration, we
generated speciﬁc QALE for multiple individuals
deﬁned by standard 10-year risk tables.16 Separate tables
are estimated for men and women, for the lowest and
highest ﬁfths of SIMD, and by smoking status with the
assumption of 20 cigarettes per day for smokers. All risk
proﬁles were attributed an average family history (pro-
portion=0.26) and diabetes (proportion=0.15) derived
from SHHEC. This was for exposition purposes to avoid
producing additional tables for individuals with and
without family history, and with and without diabetes,
given journal restrictions on the number of tables. In
principle, the model can take into account all ASSIGN
risk factors when estimating QALE and health service
costs, producing speciﬁc estimates, charts and tables as
required.
Estimating lifetime health service costs
The linked SHHEC-SMR dataset recorded all hospitalisa-
tions, both CVD and non-CVD related. These were
costed using method 1 in Geue,17 and the total cost of a
continuous inpatient stay (CIS) was estimated. This is
driven by the principal cause of admission and add-
itional ‘hotelling’ costs if the observed length of stay
exceeded the ‘trim point’ of the principal event. Costs
are accumulated in all annual cycles of the model (see
online supplementary equations 6 and 7), before the
ﬁrst event and following a non-fatal event.
These estimates are applied in the model by using the
same KMSA estimator approach used to generate QALE.
In this case, annual costs are weighted by the survival
probability of an individual, and the area under the
curve is summed to estimate cumulative lifetime costs.
Figure 2 Process of quality
adjustment. CHD, coronary heart
disease; HRQoL, health-related
quality of life.
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This process is illustrated using the same 60-year male
proﬁle as before.
Generating expected lifetime health service costs
To reiterate, an individual faces 400 scenarios on enter-
ing the model deﬁned by the type and timing of the
ﬁrst event (4 ﬁrst events×100 model cycles). Each scen-
ario results in a different lifetime cost estimate. To gen-
erate overall, expected, lifetime costs, the probability of
each scenario occurring (taken from the cumulative
incidence of the ﬁrst four events) is multiplied by its
associated cost estimate, and summed. For consistency,
we illustrate the model’s ability to discriminate by esti-
mating lifetime costs for multiple individuals deﬁned by
10-year risk tables.
Preparing model to be used for cost-effectiveness analysis
The model can be used to estimate the cost-effectiveness
of interventions aimed at modifying the ASSIGN risk
factors. Potential interventions may include pharmaceu-
ticals, lifestyle interventions and legislative changes.
Three main inputs are used in the model: (1) the cost
of the intervention(s) which may include one-off costs
(eg, legislation) or periodic costs (eg, pharmaceuticals);
(2) the associated evidence (efﬁcacy or effectiveness)
regarding the interventions’ impact on reducing risk
factors and (3) relevant adherence/compliance assump-
tions where necessary, which can be tailored to particu-
lar individual risk proﬁles, such as age, sex and
socioeconomic deprivation.
First, preintervention individual risk proﬁles are run
through the model to estimate baseline life expectancy,
QALE and costs. Second, risk proﬁles are adjusted post-
intervention (using trial evidence or conducting a
‘what-if’ analysis) and individuals are rerun through the
model. The difference in life expectancy, QALE and
costs (net of intervention costs) is then calculated to
generate an incremental cost-effectiveness ratio.
Discount rates can be applied according to guidance.
For instance, the model currently discounts life expect-
ancy, QALE and costs at a rate of 3.5% for health tech-
nology interventions and 1.5% for public health
interventions. This approach follows guidance from
NICE.2 18 19
The model can also incorporate evidence relating to
the impact of intervention(s) on event rates (eg, CHD).
To do this, the model estimates the necessary changes to
relevant risk factors to obtain reported event rates. This
can be done using appropriate literature and expert
opinion. Further, by converting event rates into assumed
risk factor reductions, the model is then able to estimate
the impact of interventions on all ﬁrst four events (non-
fatal CHD, non-fatal CBVD, fatal CVD and fatal
non-CVD).
Uncertainty analysis: There is an uncertainty regarding
predictions of event risks, life expectancy, quality adjust-
ment and costs. The model is capable of undertaking a
full uncertainty analysis,3 20 21 including probabilistic
sensitivity analysis (PSA) by varying all parameters at
once; an analysis of extremes by taking the limits of the
CIs to produce expected, best-case and worst-case scen-
arios; or a simple one-way sensitivity analysis by varying
one parameter at a time. Further, the model can directly
vary the discount rate as part of a scenario analysis. The
online supplementary appendix details parameter esti-
mates that enable uncertainty analysis to be undertaken,
including the variance–covariance relationship between
the ASSIGN risk factors and events, and the associated
Cholesky decomposition matrixes used in PSA.
Example case study: To illustrate the readiness of the
model to undertake cost-effectiveness analysis, the paper
builds on an example from the ﬁrst paper. The SHeS
2009 was used to estimate average risk proﬁles for men
and women aged 60 years across ﬁfths of socioeconomic
Figure 3 Process of attaching
costs. CHD, coronary heart
disease.
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Table 1 Discounted quality-adjusted life expectancy (QALE) for men and women for least and most socioeconomically deprived
Men—least deprived fifth Women—least deprived fifth
Non-smoker Smoker Non-smoker Smoker
Age 70 years Age 70 years Age 70 years Age 70 years
Systolic
blood
pressure
(mm Hg)
180 80.9 80.7 80.7 80.6 80.6 78.8 78.8 78.9 78.9 78.9 Systolic
blood
pressure
(mm Hg)
180 81.9 81.8 81.6 81.6 81.5 79.1 79.1 79.0 79.1 79.1
160 81.4 81.3 81.3 81.2 81.1 79.2 79.3 79.4 79.4 79.4 160 82.5 82.5 82.3 82.2 82.2 79.7 79.7 79.7 79.7 79.7
140 81.8 81.7 81.8 81.7 81.6 79.6 79.7 79.8 79.9 79.9 140 83.1 83.0 82.9 82.8 82.7 80.3 80.4 80.3 80.3 80.3
120 82.1 82.2 82.2 82.1 82.1 79.9 80.1 80.2 80.3 80.3 120 83.7 83.6 83.4 83.3 83.3 80.9 80.9 80.9 80.9 80.9
100 82.4 82.5 82.6 82.5 82.5 80.1 80.4 80.6 80.6 80.7 100 84.1 84.1 83.9 83.8 83.8 81.3 81.5 81.4 81.4 81.4
Age 60 years Age 60 years Age 60 years Age 60 years
180 74.8 74.6 74.6 74.5 74.5 72.8 72.8 72.9 72.9 72.9 180 75.6 75.5 75.3 75.3 75.3 72.9 72.9 72.9 72.9 73.0
160 75.2 75.1 75.1 75.0 74.9 73.2 73.3 73.3 73.4 73.4 160 76.1 76.1 75.9 75.8 75.8 73.5 73.6 73.5 73.5 73.6
140 75.6 75.5 75.5 75.4 75.4 73.5 73.6 73.8 73.8 73.8 140 76.6 76.6 76.4 76.3 76.3 74.1 74.2 74.1 74.1 74.1
120 75.9 75.9 75.9 75.8 75.8 73.8 74.0 74.1 74.2 74.2 120 77.1 77.0 76.8 76.8 76.7 74.6 74.7 74.6 74.6 74.6
100 76.1 76.2 76.2 76.2 76.1 74.0 74.3 74.5 74.5 74.5 100 77.4 77.4 77.3 77.2 77.2 75.0 75.1 75.1 75.1 75.1
Age 50 years Age 50 years Age 50 years Age 50 years
180 68.2 68.1 68.1 68.0 68.0 66.5 66.6 66.7 66.8 66.8 180 68.8 68.7 68.6 68.6 68.6 66.5 66.6 66.6 66.6 66.7
160 68.6 68.5 68.5 68.4 68.4 66.9 67.0 67.1 67.1 67.2 160 69.2 69.1 69.0 69.0 69.0 67.1 67.1 67.1 67.1 67.2
140 68.9 68.9 68.8 68.8 68.7 67.2 67.3 67.5 67.5 67.5 140 69.6 69.5 69.4 69.4 69.4 67.6 67.6 67.6 67.6 67.6
120 69.2 69.2 69.2 69.1 69.1 67.5 67.6 67.8 67.8 67.8 120 70.0 69.9 69.8 69.7 69.7 67.9 68.0 68.0 68.0 68.0
100 69.4 69.4 69.4 69.3 69.3 67.6 67.9 68.0 68.1 68.0 100 70.3 70.2 70.1 70.0 70.0 68.3 68.4 68.4 68.4 68.4
Age 40 years Age 40 years Age 40 years Age 40 years
180 61.1 61.0 61.0 60.9 60.9 59.8 59.9 59.9 60.0 60.0 180 61.4 61.3 61.3 61.2 61.2 59.7 59.7 59.8 59.8 59.8
160 61.4 61.3 61.2 61.2 61.2 60.1 60.1 60.3 60.3 60.3 160 61.7 61.6 61.6 61.5 61.5 60.1 60.1 60.1 60.2 60.2
140 61.6 61.5 61.5 61.5 61.4 60.3 60.4 60.5 60.6 60.6 140 62.0 61.9 61.9 61.8 61.8 60.4 60.5 60.5 60.5 60.5
120 61.8 61.7 61.7 61.7 61.7 60.5 60.6 60.7 60.8 60.8 120 62.2 62.2 62.1 62.0 62.0 60.7 60.8 60.8 60.8 60.8
100 61.9 61.9 61.9 61.9 61.9 60.6 60.8 60.9 60.9 60.9 100 62.5 62.4 62.3 62.3 62.2 61.0 61.1 61.0 61.0 61.1
3 5 7 9 10 3 5 7 9 10 3 5 7 9 10 3 5 7 9 10
Total/HDL
cholesterol ratio
Total/HDL
cholesterol ratio
Men—most deprived fifth Women—most deprived fifth
Non-smoker Smoker Non-smoker Non-Smoker
Age 70 years Age 70 years Age 70 years Age 70 years
Systolic blood
pressure
(mm Hg)
180 78.8 78.6 78.5 78.4 78.3 76.8 76.8 76.8 76.7 76.7 Systolic blood
pressure
(mm Hg)
180 80.4 80.3 80.2 80.1 80.1 77.9 77.9 77.9 77.9 77.9
160 79.3 79.1 79.0 78.9 78.8 77.2 77.2 77.2 77.2 77.1 160 81.0 80.9 80.7 80.6 80.6 78.4 78.5 78.4 78.4 78.4
140 79.6 79.5 79.5 79.4 79.3 77.5 77.6 77.6 77.6 77.6 140 81.5 81.4 81.3 81.1 81.1 78.9 79.0 78.9 78.9 78.9
120 79.9 79.9 79.9 79.9 79.8 77.7 77.9 78.0 78.0 78.0 120 82.0 81.9 81.7 81.6 81.6 79.4 79.5 79.4 79.4 79.4
100 80.1 80.3 80.3 80.2 80.2 77.9 78.1 78.3 78.3 78.3 100 82.5 82.4 82.2 82.1 82.0 79.8 79.9 79.8 79.8 79.8
Continued
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Table 1 Continued
Men—most deprived fifth Women—most deprived fifth
Non-smoker Smoker Non-smoker Non-Smoker
Age 60 years Age 60 years Age 60 years Age 60 years
180 72.6 72.3 72.2 72.1 72.0 70.5 70.4 70.4 70.4 70.4 180 74.2 74.1 73.9 73.8 73.8 71.7 71.7 71.6 71.7 71.7
160 73.1 72.8 72.7 72.6 72.5 70.9 70.9 70.9 70.9 70.9 160 74.7 74.6 74.4 74.3 74.3 72.2 72.2 72.2 72.2 72.2
140 73.4 73.3 73.2 73.1 73.0 71.2 71.3 71.4 71.3 71.3 140 75.2 75.1 74.9 74.8 74.7 72.7 72.7 72.7 72.7 72.7
120 73.8 73.7 73.7 73.5 73.4 71.5 71.7 71.7 71.7 71.7 120 75.6 75.5 75.3 75.2 75.2 73.1 73.2 73.1 73.1 73.1
100 74.0 74.0 74.0 73.9 73.9 71.7 71.9 72.1 72.1 72.1 100 76.0 75.9 75.7 75.6 75.5 73.5 73.6 73.5 73.5 73.5
Age 50 years Age 50 years Age 50 years Age 50 years
180 66.3 66.0 65.9 65.8 65.7 64.4 64.3 64.4 64.3 64.3 180 67.6 67.5 67.4 67.3 67.3 65.4 65.4 65.4 65.4 65.5
160 66.7 66.4 66.4 66.2 66.1 64.8 64.8 64.8 64.8 64.7 160 68.0 67.9 67.8 67.7 67.6 65.9 65.9 65.9 65.9 65.9
140 67.0 66.8 66.8 66.6 66.6 65.1 65.1 65.2 65.2 65.1 140 68.4 68.3 68.1 68.1 68.0 66.3 66.3 66.3 66.3 66.3
120 67.3 67.2 67.1 67.0 67.0 65.4 65.5 65.5 65.5 65.5 120 68.7 68.6 68.4 68.4 68.3 66.6 66.7 66.7 66.7 66.7
100 67.5 67.5 67.5 67.4 67.3 65.5 65.7 65.8 65.8 65.8 100 69.0 68.9 68.8 68.7 68.6 67.0 67.1 67.0 67.0 67.0
Age 40 years Age 40 years Age 40 years Age 40 years
180 59.4 59.2 59.1 59.0 59.0 58.0 57.9 57.9 57.9 57.9 180 60.4 60.3 60.2 60.2 60.2 58.7 58.8 58.7 58.8 58.8
160 59.8 59.6 59.5 59.4 59.3 58.3 58.2 58.3 58.2 58.2 160 60.7 60.6 60.5 60.5 60.4 59.1 59.1 59.1 59.1 59.1
140 60.0 59.9 59.8 59.7 59.6 58.5 58.5 58.6 58.6 58.5 140 61.0 60.9 60.8 60.7 60.7 59.4 59.5 59.4 59.4 59.4
120 60.3 60.2 60.1 60.0 59.9 58.7 58.8 58.8 58.8 58.8 120 61.3 61.2 61.1 61.0 60.9 59.7 59.7 59.7 59.7 59.7
100 60.4 60.4 60.4 60.2 60.2 58.9 59.0 59.1 59.1 59.0 100 61.5 61.4 61.3 61.2 61.2 59.9 60.0 60.0 60.0 60.0
3 5 7 9 10 3 5 7 9 10 3 5 7 9 10 3 5 7 9 10
Total/HDL
cholesterol ratio
Total/HDL
cholesterol ratio
HDL, high-density lipoprotein.
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Table 2 Discounted lifetime hospital costs for men and women for least and most socioeconomically deprived
Men—least deprived fifth Women—least deprived fifth
Non-smoker Smoker Non-smoker Smoker
Age 70 years Age 70 years Age 70 years Age 70 years
Systolic
blood
pressure
(mm Hg)
180 46.4 44.8 44.5 44.6 44.7 41.6 41.5 42.1 42.7 43.1 Systolic
blood
pressure
(mm Hg)
180 50.4 49.0 47.9 48.1 48.1 41.7 41.6 41.5 41.9 42.2
160 48.1 45.9 45.2 45.0 45.0 43.1 42.7 43.0 43.4 43.7 160 52.9 50.6 49.0 48.9 48.7 44.4 43.7 43.3 43.4 43.7
140 49.7 47.1 46.0 45.4 45.3 44.5 43.8 43.8 44.0 44.2 140 55.5 52.4 50.2 49.7 49.4 47.2 45.9 44.8 44.8 45.0
120 51.5 48.5 47.0 46.0 45.8 45.9 44.9 44.8 44.6 44.7 120 58.5 54.5 51.7 50.5 50.2 50.3 48.3 46.6 46.3 46.1
100 53.2 49.9 48.2 46.9 46.5 47.2 46.2 45.7 45.4 45.2 100 61.9 57.0 53.4 51.7 51.3 53.3 50.8 48.6 47.7 47.6
Age 60 years Age 60 years Age 60 years Age 60 years
180 53.5 52.4 52.6 53.3 53.7 52.2 52.6 53.7 54.9 55.6 180 56.4 55.9 55.4 56.0 56.6 51.7 52.0 52.2 53.1 53.8
160 54.5 52.5 52.2 52.5 52.8 53.2 52.9 53.6 54.5 55.0 160 58.1 56.5 55.4 55.6 56.1 53.8 53.4 53.1 53.7 54.3
140 55.7 52.9 52.0 51.9 52.0 54.3 53.4 53.5 54.1 54.4 140 60.1 57.3 55.5 55.3 55.4 56.2 54.8 53.9 54.1 54.6
120 57.2 53.6 52.1 51.6 51.5 55.6 54.0 53.6 53.8 54.0 120 62.6 58.5 55.8 55.3 55.1 58.7 56.4 54.9 54.7 55.0
100 58.8 54.7 52.7 51.6 51.4 56.9 54.8 54.0 53.8 53.8 100 65.5 60.0 56.7 55.4 55.2 61.5 58.2 56.0 55.5 55.4
Age 50 years Age 50 years Age 50 years Age 50 years
180 55.1 55.0 56.0 57.5 58.4 57.7 59.0 60.7 62.6 63.7 180 57.0 57.4 57.8 59.2 60.1 56.5 57.4 58.3 59.8 60.8
160 55.4 54.2 54.5 55.6 56.3 58.0 58.2 59.4 61.0 61.9 160 57.7 56.9 56.8 57.7 58.6 57.7 57.9 58.0 59.2 60.2
140 56.0 53.7 53.4 53.9 54.4 58.5 57.7 58.3 59.4 60.1 140 59.0 56.8 55.9 56.4 57.1 59.3 58.2 57.9 58.7 59.5
120 57.2 53.7 52.7 52.7 52.9 59.4 57.7 57.5 58.1 58.6 120 60.7 57.2 55.5 55.5 55.7 61.3 59.0 57.9 58.3 58.8
100 58.6 54.2 52.5 51.9 51.9 60.6 57.9 57.2 57.2 57.5 100 62.8 58.1 55.4 54.8 54.9 63.4 60.2 58.3 58.1 58.5
Age 40 years Age 40 years Age 40 years Age 40 years
180 52.0 53.2 54.9 57.1 58.3 57.5 59.8 62.2 64.8 66.2 180 53.0 54.7 56.0 58.0 59.3 55.7 57.8 59.5 61.6 62.7
160 51.6 51.5 52.6 54.4 55.4 57.1 58.1 59.9 62.1 63.3 160 53.0 53.5 54.1 55.9 57.0 56.1 57.2 58.2 60.1 61.2
140 51.8 50.4 50.8 52.0 52.8 57.0 56.9 57.9 59.6 60.7 140 53.5 52.7 52.6 53.8 54.8 57.0 56.8 57.2 58.7 59.5
120 52.4 49.8 49.4 50.1 50.7 57.5 56.1 56.4 57.6 58.4 120 54.5 52.3 51.5 52.2 52.8 58.1 56.8 56.3 57.3 58.1
100 53.6 49.8 48.6 48.7 49.0 58.4 55.9 55.4 56.0 56.5 100 56.1 52.4 50.9 51.0 51.3 60.0 57.2 56.0 56.4 57.0
3.0 5.0 7.0 9.0 10.0 3.0 5.0 7.0 9.0 10.0 3 5 7 9 10 3 5 7 9 10
Total/HDL
cholesterol ratio
Total/HDL
cholesterol ratio
Men—most deprived fifth Women—most deprived fifth
Non-smoker Smoker Non-smoker Smoker
Age 70 years Age 70 years Age 70 years Age 70 years
Systolic
blood
pressure
(mm Hg)
180 40.3 37.8 36.8 36.2 35.9 34.4 33.5 33.3 33.2 33.3 Systolic
blood
pressure
(mm Hg)
180 49.7 47.7 46.2 45.8 45.9 41.4 40.9 40.6 40.8 41.0
160 42.3 39.4 38.1 37.2 36.8 36.1 34.9 34.6 34.3 34.3 160 52.3 49.4 47.4 46.6 46.5 43.9 42.8 41.9 42.0 42.1
140 44.3 41.1 39.5 38.3 37.8 37.7 36.3 35.9 35.4 35.3 140 55.4 51.6 48.8 47.5 47.3 46.7 44.9 43.5 43.2 43.0
120 46.2 42.9 41.0 39.6 39.0 39.2 37.9 37.1 36.6 36.2 120 58.9 53.8 50.4 48.8 48.2 49.7 47.3 45.3 44.4 44.4
100 48.1 44.8 42.7 41.0 40.3 40.6 39.3 38.4 37.7 37.4 100 62.5 56.8 52.6 50.4 49.7 52.7 49.7 47.3 46.2 45.9
Age 60 years Age 60 years Age 60 years Age 60 years
180 49.2 46.7 45.9 45.7 45.7 46.2 45.2 45.3 45.6 45.9 180 58.4 56.6 55.7 55.9 56.3 53.8 53.7 53.4 54.3 54.6
160 50.9 47.6 46.3 45.7 45.6 47.7 46.1 45.8 45.8 46.0 160 60.3 57.4 55.7 55.5 55.6 55.8 54.6 54.0 54.5 54.7
140 52.7 48.7 46.9 45.9 45.7 49.2 47.2 46.5 46.2 46.2 140 62.5 58.6 56.1 55.3 55.1 58.1 56.1 54.7 54.6 54.8
120 54.7 50.2 47.9 46.5 46.0 50.8 48.5 47.4 46.7 46.6 120 65.5 60.3 56.9 55.6 55.1 61.0 57.9 55.8 55.2 55.2
100 56.7 51.8 49.2 47.4 46.8 52.4 49.8 48.4 47.5 47.1 100 69.0 62.4 58.2 56.2 55.6 64.2 60.2 57.4 56.1 56.0
Continued
8
Law
son
KD,Lew
sey
JD,Ford
I,etal.Open
Heart2016;3:e000140.doi:10.1136/openhrt-2014-000140
O
p
e
n
H
e
a
rt
deprivation. The ﬁrst paper generated undiscounted life
expectancy predictions. This exercise was repeated by
running the same proﬁles through the model to esti-
mate QALE and costs. We then conducted a ‘what-if’
exercise, where individuals switch to ‘perfect’ risk factor
proﬁles deﬁned in reference to 10-year risk tables as
non-smokers, systolic blood pressure of 100 and a ratio
of total cholesterol to HDL cholesterol of 3. For illustra-
tive purposes, it is assumed that individuals immediately
switch risk proﬁles and acquire the associated life
expectancy and QALE. In practice, the model can
accommodate evidence regarding reversibility of risk
and lag effects for instance. The illustration then esti-
mates the maximum theoretical beneﬁt on life expect-
ancy, QALE and lifetime hospital costs if individuals
switched to a perfect risk proﬁle. Mean estimates are
provided, both undiscounted and discounted.
RESULTS
Generating QALE and lifetime costs
Figure 2 illustrates the KMSA estimator approach when
quality adjusting survival for a man aged 60 years follow-
ing a non-fatal CHD event, as deﬁned under the
Methods section. The composite utility decrement (ie,
the amount by which HRQoL falls due to expected
further non-fatal CVD events) is shown in shaded bars.
This increases over time, reﬂecting the increasing prob-
ability of incurring CVD events as an individual ages.
Annual estimates are used to weight an individual’s sur-
vival probability, which declines over time.
Figure 3 illustrates a similar approach to generate life-
time costs for the same man aged 60 years. Costs initially
decrease postevent as the surviving individual requires
less care, and then steadily increase as comorbidities
accumulate with age. Annual estimates are weighted by
an individual’s survival curve.
Table 1 illustrates discounted QALE using the risk pro-
ﬁles of 10-year risk tables and adjusts for all three ele-
ments of quality of life: background morbidity, the
impact of experiencing a ﬁrst non-fatal CVD event and
the impact of experiencing subsequent non-fatal CVD
events. The table is divided into four segments (a–d)
representing sex and socioeconomic deprivation status
(highest and lowest ﬁfths), with further division by
smoking status and four 10-year age bands from 40 to
70 years. The ratios of total cholesterol to HDL choles-
terol are represented along the ‘x-axis’ and systolic
blood pressure values are represented along the ‘y-axis’.
The tables illustrate several gradients where, for an
otherwise identical risk factor proﬁle, discounted QALE
are higher for women compared with men, non-smokers
compared with smokers, least deprived ﬁfth compared
with the most deprived ﬁfth and for older compared
with younger individuals (due to conditional life
expectancy).
Table 2 follows a similar format and illustrates that
higher discounted costs are associated with healthier
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risk proﬁles given longer life expectancies and the accu-
mulation of comorbidities. Several gradients are evident
with costs higher for women, the least deprived and
younger individuals (due to higher cumulative life
expectancy). Smokers in the age groups of 40 and
50 years tend to have higher costs with the expectation
of early onset of related health-related conditions.
Demonstrating the CVD policy model
Figure 4 illustrates the potential gains from modifying the
‘average’ risk proﬁles of 60 year old men and women in
the general population, across ﬁfths of socioeconomic
deprivation (SIMD), to the ‘ideal’ risk proﬁles according
to clinical guidelines. Separate estimates are shown for
undiscounted life expectancy and discounted QALE. For
each column, the dark shading illustrates baseline life
expectancy before risk factor modiﬁcation, the light
shading illustrates the potential gain from moving to a
‘perfect’ risk proﬁle and revised estimates of undiscounted
life expectancy and discounted QALE are provided at the
top.
Potential gains from modifying risk factors increase
with deprivation status. Women also tend to have greater
potential to beneﬁt, except within the most deprived
ﬁfth. Before risk factor modiﬁcation, men in the least
deprived ﬁfth (SIMD 1) have a 7% higher life
expectancy than the most deprived ﬁfth (SIMD 5) and a
3.5% higher discounted QALE. Following risk factor
modiﬁcation, the gradient closes to 4.8% and 2.7%,
respectively. For women, the least deprived ﬁfth have
5.5% higher life expectancy than the most deprived ﬁfth
and 2.3% higher discounted QALE. Following risk factor
modiﬁcation, the gradient closes to 2.7% and 1.9%,
respectively.
Figure 5 illustrates that individuals in the least
deprived ﬁfth (compared with the most deprived ﬁfth)
and women (compared with men) have higher costs
consistent with longer life expectancies. Shifting indivi-
duals to a perfect risk proﬁle results in increasing costs
across all individuals given longer life expectancies. The
effect of discounting is to give progressively less weight
to the future and so narrows the gradient in lifetime
costs between groups.
DISCUSSION
Summary
We built a policy model capable of estimating life
expectancy, QALE and lifetime hospital costs for indivi-
duals deﬁned by the ASSIGN risk factors. The model
can be used to estimate the cost-effectiveness of primary
prevention interventions and assess impacts on health
Figure 4 Risk factor modification on men and women aged 60 years—undiscounted life expectancy and discounted QALE.
SIMD, Scottish Index of Multiple Deprivation; QALE, quality-adjusted life expectancy.
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inequalities, which is the principal rationale of primary
prevention in Scotland.6
Strengths
A strength of the model is the ability to assess cost-
effectiveness over the lifetime of individuals. This is in
contrast, for instance, with the NICE Programme
Development Group where the potential impacts of
changes in legislation (eg, salt reduction) were projected
over a period of 10 years.22
The model can be used to estimate the impact of a
wide range of interventions aimed at reducing modiﬁ-
able ASSIGN risk factors, including total cholesterol,
HDL cholesterol, systolic blood pressure and cigarettes
smoked per day. In this sense, the model may be
described as a ‘generic model’, in contrast with ‘bespoke
models’ built for speciﬁc interventions focused on par-
ticular risk factors. Further, the relationship between risk
factors and events was estimated on a continuous basis
where possible, enabling more ﬁne-grained estimates
compared with most other policy models that allocate
individuals to subgroups (eg, a speciﬁed range of a risk
factor).
The model can also be used to undertake ‘what-if’
analysis to assess the potential impact of individually tar-
geted and population interventions, including ‘thresh-
old analysis’ to vary the cost and/or effect of an
intervention to assess the point at which an intervention
becomes cost-effective.20
The policy model can be described as a state-transition
model and took a competing risk approach (see the ﬁrst
paper) to estimate the relationship between risk factors
and CVD and non-CVD death (eg, from cancer and
respiratory disease). Consequently, the model can esti-
mate the impact of risk factor modiﬁcation beyond CVD
events when conducting cost-effectiveness analysis.
The model could be used in practice to assess the cost-
effectiveness of single interventions or multifactorial pro-
grammes, involving simultaneous interventions, that
impact on the modiﬁable risk factors. For instance,
Scotland’s primary prevention programme, Keep Well,
screens individuals using the ASSIGN risk tool with
potential referral to a wide range of pharmaceutical and
lifestyle interventions.6 At present, no economic evalu-
ation has been undertaken, and there is an absence of
robust economic evidence for multifactorial pro-
grammes in general.
Figure 5 Risk factor modification on men and women aged 60 years—undiscounted and discounted lifetime hospital costs.
SIMD, Scottish Index of Multiple Deprivation.
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A potentially important feature of the model is that by
using the ASSIGN risk factor variables, which includes a
measure of socioeconomic deprivation (SIMD), the
model can take into account the impact of interventions
on health inequalities. The model estimated the poten-
tial impacts if average modiﬁable risk proﬁles of men
and women aged 60 years within SIMD ﬁfths were
switched to ‘perfect’ risk proﬁles. It was shown that
primary prevention could potentially close health
inequalities with more deprived groups having the most
to gain. However, this exercise was for illustration to
demonstrate the functionality of the model. Trial evi-
dence is crucial, especially to understand reversibility of
risks which may decrease with age, and long-term adher-
ence/compliance which may be lower in socioeconomic-
ally disadvantaged groups. Trials and modelling can
complement one another, with the latter projecting
longer term clinical and economic outcomes where
necessary.23
The model adjusts relatively comprehensively for mor-
bidity impacts, including background morbidity and the
impacts of experiencing ﬁrst and subsequent non-fatal
CVD events. Further, the model estimates the impact of
extending life expectancy on hospitalisation costs. This
is potentially important as prevention is likely to extend
life expectancy and lead to individuals accumulating
comorbidities.24 25
A full uncertainty analysis, including PSA, can
be undertaken. Further, the model is capable of
undertaking decision analysis, including pretrial
modelling, trial evaluation and value of information
analysis.3 18 20 21
Finally, a strength of the twinned papers and online
supplementary appendix is the detailed reporting of
data sources, methods, validation and calibration exer-
cises. This practice follows recent modelling guidelines
to enhance the transparency, peer review and use of
models.26
Limitations
There are several limitations to the model, in addition
to those discussed in the ﬁrst paper. A major limitation
is that only hospitalisations are included when estimating
health service costs. Not included, due to lack of data,
are costs relating to primary care, prescriptions and com-
munity care. There is a need to consider linking
primary and secondary healthcare data which are not
routinely available across Scotland, at present. In evaluat-
ing primary prevention interventions, economic proto-
cols should track all relevant costs in addition to
intervention and hospitalisation cost(s), conditional on
the perspective of the analysis. All such information
could then be easily incorporated into the model to
assess cost-effectiveness.
The utility decrements estimated for use in the policy
model may not perfectly match the events incurred by
individuals (eg, for CHD, the decrement for myocardial
infarction is used). However, there is a lack of estimated
utility decrements for the general population, none for
Scotland, and these were the events considered within
the SHeS.
Physical activity, which is an independent risk factor
for CVD, is not part of the ASSIGN risk tool and there-
fore not part of the policy model. No other prominent
CVD risk tool used routinely in clinical practice (that we
are aware of) includes physical activity. Research has
shown that there are diminishing marginal returns to
adding risk factors,27 ASSIGN includes nine risk factors,
and there is similar predictive ability between risk
scores.28 To estimate the impact of physical activity inter-
ventions, the model could modify relevant ASSIGN risk
factors (eg, systolic blood pressure, total cholesterol,
HDL cholesterol) to match trial evidence concerning
risk factors or event rates.
The model takes a ‘healthcare perspective’ with the
focus on estimating the impact on (quality-adjusted) life
expectancy to individuals and health service costs. This
approach is consistent with guidance to undertake cost-
effectiveness and cost-utility analysis.1 However, not con-
sidered at present are potential knock-on impacts of
interventions on, for instance, carers and productivity.19
The model was developed using Scottish data sources
and intended to be used in Scotland. However, the
model could be used in other settings by recalibrating to
the population of interest. For instance, the
Framingham risk tool was developed in the USA but has
been recalibrated to be used in England.16 Further,
policy models such as the CHD Policy Model29 and
IMPACT30 have been recalibrated to populations in dif-
ferent countries.
Overall, these limitations offer an opportunity for
further research with guidance recommending that
models be continuously improved, validated and cali-
brated to contemporary populations.3
Policy applications
This CVD policy model is intended to inform primary
prevention policy aimed at avoiding premature morbid-
ity and mortality and associated health service costs. By
using the same variables employed in the ASSIGN risk
equation, there is alignment between the clinical tools
currently used in Scotland to screen and prioritise indi-
viduals for intervention with this new policy model that
can be used to evaluate the cost-effectiveness of individu-
ally targeted and population interventions aimed at
modifying risk. Further, the model can assess impacts on
health inequalities. Overall, the policy model attempts to
integrate CVD risk estimation, individual patient
decision-making and societal policymaking into a cohe-
sive whole.
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